Colorectal cancer is the second most common form of malignancy encountered in the Western World (Silverberg & Lubera, 1988) . Following initial curative resection of the primary colorectal tumour, 35% to 60% of the patients die with liver metastases (Kemeny & Golbey, 1980; August et al., 1984) .
The presence of liver metastases is a major prognostic factor, survival being largely determined by the extent of hepatic disease at presentation (Wood et al., 1976; Cady, 1983; Kemeny et al., 1989) . Resection of the hepatic metastases is the only hope for prolonged survival, increasing the 5 year survival rates from 3% to about 30% (Wagner et al., 1984; Hughes et al., 1986) . Because colorectal carcinoma is highly resistant to chemotherapy, at present little can be offered to patients with irresectable metastases. However, many anticancer agents show steep dose-response relationships and this has encouraged the development of treatment modalities allowing exposure to higher local drug concentrations. Based upon the concept that liver metastases derive their blood flow mainly from the hepatic artery, continuous hepatic artery infusion (HAI) with fluorodeoxyuridine has been widely used, resulting in significantly higher response rates, but not in prolonged survival (Kemeny et al., 1987; Chang et al., 1987; Hohn et al., 1989; Martin et al., 1990) .
Various research groups have experimented with an isolated liver perfusion (ILP) technique (Aigner et al., 1982; Aigner et al., 1983; Skibba, 1983, van de Velde et al., 1986; Radnell et al., 1990) . Although ILP with 5-fluorouracil (FUra) and mitomycin C (MMC) has recently been applied in patients by Aigner et al. (1988) , data on the effectiveness of this approach are not yet available. In experimental studies in rats, the effectiveness of ILP has been reported for FUra (Radnell et al., 1990; Marinelli et al., 1990b) and MMC (Marinelli et al., 1991) . Only with MMC complete remissions and a significantly prolonged survival has been reported (Marinelli et al., 1991) . In rats, hepatotoxic side effects of MMC was dose limiting (Marinelli et al., 1990a) . In six out of seven evaluable patients treated with 30 mg m-2 of MMC in ILP an objective response was seen (> 50% tumour volume reduction on CT). Unfortunately, as in rats hepatotoxicity did not allow further dose escalation (manuscript in preparation).
The present study focussed on the application of melphalan in isolated liver perfusion in the rat. Melphalan was chosen because (1) in contrast with MMC (Lazarus et al., 1982) melphalan resulted in only mild, asymptomatic, and transient elevation of liver function tests when patients were treated with five times higher drug doses than the recommended single bolus doses i.v. and autologous bone marrow transplantation (Lazarus et al., 1983; Leff et al., 1986) , (2) a small increase in the intracellular concentration of melphalan may translate into dramatic therapeutic improvement (Vistica, 1983) , (3) an impressively high overall response rate of 47% to high dose melphalan (180 mg m-2) was noted in patients with colon cancer (Leff et al., 1986) and (4) recently four patients have been treated with 0.5 mg kg-' melphalan in isolated liver perfusion resulting in exposure of liver and tumours to ten times higher drug concentrations than after administration of the same dose i.v. (Hafstrom et al., 1990) without liver toxicity.
In rats first the dose limiting toxicity and maximally tolerated dose in ILP and HAI were determined. Subsequently, these treatment modalities were compared with respect to the maximally achievable concentration of melphalan in tumour tissue and the antitumour effect.
The differences in the results of this study with melphalan and a previously published study with MMC (Marinelli et al., 1990a) will be discussed.
Materials and methods

Rats
Wistar derived, inbred male WAG/Ola rats (Harlan/CPB, Zeist, The Netherlands) were used. At the time of tumour inoculation, the weight of the rats was 260 to 360 g in the toxicity and pharmacokinetic study and 230 to 280 g in the antitumour effect study. The rats were fed laboratory chow and water ad libitum.
Surgical procedures
All operative procedures were carried out under clean but not sterile conditions, using a microscope (Applied Fiberoptics, Southbridge, MA, USA) at 20 times magnification. Anaesthesia was induced and maintained by ether.
(1) Isolated liver perfusion with two inflow limbs This technique has been previously described in detail (de Brauw et al., 1988; Marinelli et al., 1990a) . In short, after performing a midline abdominal incision cannulas were inserted into the gastroduodenal artery and the pyloric vein with their tips in the hepatic artery and portal vein respectively. For the outflow, one cannula was inserted into the caval vein. To isolate the liver, all normal in-and outflow routes were clamped, the caval vein between liver and diaphragm and between right renal vein and the cannula, the aorta proximal of the coeliac axis, the common hepatic artery and portal vein just proximal of the cannulas. The outflow of the liver was collected in a reservoir/oxygenator with heat exchanger and then reinfused simultaneously into the portal vein (20 ml min -') and hepatic artery (4.5 ml minm-). The perfusate consisted of blood, Haemaccel (Hoechst, Amsterdam, The Netherlands), heparin (50 U) and bicarbonate to adjust pH to 7.3. The temperature of the perfusate was regulated at 38C and the oxygen saturation was 99%. Melphalan was injected as a bolus in the reservoir and perfusion was carried out for 25 min. At the end of the perfusion a washout was performed with saline. The total operation time was 2-2.5 h.
(2) Hepatic artery infusion A cannula was inserted into the gastroduodenal artery with the tip in the hepatic artery. During a 2 min bolus melphalan infusion, the common hepatic artery was clamped to prevent retrograde flow into the coeliac axis and the aorta. The total operation time was 20-30 min.
Tumour model CC531 is a dimethylhydrazine induced adenocarcinoma of the colon, syngeneic for WAG rats (Marquet et al., 1984 ). An established cell line was maintained in culture in RPMI 1640 (Dutch modification; GIBCO Europe B.V., Breda, The Netherlands), supplemented with 10% foetal calf serum (GIBCO Limited, Paisley, Scotland), 2 mM L-glutamine, 50 fg ml-' streptomycin and 50 IU ml-' penicillin. Exponentially growing cells were harvested by trypsinisation and 5 x 105 cells in 0.05 ml Hank's Balanced Salt Solution were subcapsularly injected into the right and left main lobe of the liver. For the pharmacokinetic study, a third tumour was induced in the right accessory lobe. Ten days after inoculation, the mean cross sectional area (i x 0.25 x largest diameter x perpendicular diameter) of the tumours was 23 ± 6 mm2 (n = 68).
Melphalan
Melphalan was kindly supplied by Wellcome Pharmaceuticals B.V. (Utrecht, The Netherlands). One hundred mg melphalan was first dissolved in 1.8 ml acid alcohol solvent and 9 ml of Wellcome Deluent and subsequently diluted with sterile saline. Solutions containing 4 mg ml1 ' could be stored several weeks at -200C.
The dose-response curve of melphalan was determined for CC531 using a monolayer colony-forming assay. Two hundred and fifty cells were seeded in 6-well tissue culture plates and after 24 h the attached cells were exposed to 0, 5, 20, 40, 70, 100 and 160 gg ml-' melphalan during 20 or 60 min.
Immediately after exposure plates were washed twice and subsequently fresh medium was added. The plates were kept in a humidified incubator for 8 days at 37°C in 5% CO2. The plates were fixed by ethanol and the colonies were stained with Coomassie Brilliant Blue for counting. The surviving fraction was calculated as the number of surviving colonies in treated culture divided by that in untreated (control) culture.
The concentration of melphalan at which the surviving fraction is 0.5 is IDs.
Toxicity study
The maximally tolerated dose of melphalan for HAI was determined by assigning non-tumour-bearing rats to: 4, 6, 8
and 12 mg kg-' melphalan. Based on the results of the previously performed toxicity studies with 5-fluorouracil and mitomycin C (de Brauw et al., 1989; Marinelli et al., 1990a) the maximally tolerated dose for isolated liver perfusion was subsequently determined by treating rats with 2, 3 and 4 times the maximally tolerated dose for HAI (12, 18 and 24 mg kg-'). As a control, four rates were treated with saline 0.9% via HAI and four rats underwent ILP without drug.
Toxicity parameters Survival, weight, white blood cell (WBC) count, and serum levels of sodium (Na+), potassium (K+), urea, creatinine, serum glutamic-oxaloacetic acid (SGOT), serum glutamicpyruvic acid (SGPT) and bilirubin (BIL) were chosen to determine systemic and hepatic toxicity. After treatment the rats were weighed twice a week (on days 3 and 7). Once a week (on day 7) 1 ml blood was collected by a retro-orbital puncture to determine the WBC count and blood chemistry. WBC count was also determined on day 3. Na+, K+, urea and creatinine were determined on a Dimension (DuPont, Wilmington, DE, USA) and SGOT, SGPT and bilirubin on a RA 1000 (Technicon, Tarrytown, NY, USA).
The 5% and 95% limits of the normal value range were determined on basis of 50 blood samples collected from 50 healthy rats.
Melphalan concentration study in tissue and biofluid Rats bearing three tumours were randomly assigned to the following treatment groups: (1) 6 mg kg-' melphalan via bolus HAI (n=7); (2) 6mgkg-' (n=7) and (3) 12mgkg-' (n = 6) as bolus in the ILP circuit.
Liver biopsies of 150 to 200 mg were taken at 5, 10, 15, 20 and 25 min after bolus injection and tumour was excised at 5, 15 and 20 min (tumour weight: 70 to 150 mg). From HAI treated rats blood samples (0.5 ml) were taken at 5, 10, 15, 20 and 25 min. From ILP treated rats perfusate (0.5 ml) was sampled at 5, 10, 15 and 20 min and blood was sampled just after the washout (± 25 min). Blood or perfusate loss as a result of sampling was minimal (Marinelli et al., 1990a) .
Sample pretreatment Liver and tumour tissues were homogenised in 2 ml acetonitrile with a Polytron (Kinematica, Luzern, Switzerland) and immediately frozen in liquid nitrogen to stop metabolism of melphalan. Prior to storage samples were thawed and centrifuged at 2,500 g, an aliquot of the supernatant (500-1,000 i1) was dried in the vacuum centrifuge and stored at -30°C. Prior to analysis, samples were thawed, dissolved in the mobile phase and injected into the HPLC system. Plasma and perfusate samples were centrifuged for 15 min at 800 g and supernatants were stored at -30°C. After thawing and centrifugation at 2,500 g, supernatants of perfusate were injected into the HPLC system directly, and supernatants of plasma after deproteination by addition of 1 mol 1'1 perchloric acid, vortexing and centrifugation. All supernatants were injected into the HPLC-system within 30 min.
Together with the samples of each rat, samples for a calibration line were collected by spiking 200 mg liver in 2 ml acetonitrile with a range of melphalan concentrations; sample pretreatment and storage of these samples was identical to that described above. Calibration and analysis of the 'rat' samples was always performed on 1 day.
Recovery measurements
To determine the recovery of melphalan 2 ml mobile phase (HPLC grade acetonitrile (25 v/v %) and 0.17 mol 1' acetic acid (75%) with pH 2.8), 2 ml plasma, 2 ml perfusate or 2 ml acetonitrile (Chemicals Limited, Walkerburn, Scotland, HPLC grade) were spiked with different known amounts of melphalan. Immediately after addition-of melphalan to the plasma and perfusate, and addition of 200 mg liver to the acetonitrile solutions the samples were pretreated for HPLC analysis as described above, and subsequently injected into the HPLC system. HPLC analysis of the samples revealed that the recovery of melphalan from plasma and perfusate, and from the solution containing the homogenised liver was 61%, 88% and 84%, respectively.
High-performance liquid chromatography (Ahmed & Hsu, 1981; Bosanquet & Gilby, 1982) All melphalan concentrations were measured using HPLC. The liquid chromatograph consisted of a high pressure pump (Spectroflow 400, Kratos, Ramsey, NJ, USA) combined with an LC-UV variable wavelength detector (Spectroflow 773, Kratos, Ramsey, NJ, USA). The flow rate was 0.5 ml min-', and the UV-detector was set on 263 nm. Injection was performed with an autosampler Promis II (Spark Holland, Emmen, The Netherlands). Integration was done with a Shimadzu C-R3A (Shimadzu, Kyoto, Japan). The analytical column was a stainless steel tube, 100 mm x 3 mm i.d., packed with Nucleosil C18 (5 ,sm particles) (Macherey-Nagel, Duren, Germany).
Antitumour effect study Tumour bearing rats with two tumours each were randomly assigned to five groups: (1) untreated control (n = 8), (2) hepatic artery infusion without drug (n = 4), (3) isolated liver perfusion without drug (n = 4), (4) hepatic artery infusion with 6 mg kg-' (n = 8) and (5) isolated liver perfusion with 12 mg kg-' (n = 10). On days 0 (day of treatment), 14, 28 and 42 rats were weighed and in order to measure liver tumours laparotomy was performed. Cross sectional areas of the tumours were estimated by calliper measurements and calculated as: i x 0.25 x maximal diameter x perpendicular diameter. Rats were sacrificed at day 42 because the tumours in groups (1) to (4) weight. Rats receiving 12 mg kg' via HAI died within 3 days.
In contrast, all rats treated with 12 mg kg' in ILP survived this treatment. Treatment with 18 and 24 mg kg-' was lethal within 7 days (Figure lb) .
White blood cell count All rats treated with melphalan via HAI had a significantly decreased white blood cell count at day 3 (P<0.01) (Figure 2) . In most rats, WBC count was still significantly decreased at day 7. Following ILP with 12mgkg'1 a minor decrease in the white blood cell count was seen at day 3 and 7 ( Figure 2) . On day 14 all four rats showed a doubling of the WBC count being normalised at day 21. Moreover, after increasing the dose from 142 to 18 or 24 mg kg-' almost no white blood cell was left at day 3.
Blood chemistry In all HAI and ILP treated rats the serum levels of sodium, potassium, urea, creatinine, bilirubin, serum glutamic-oxaloacetic transaminase and serum glutamic-pyruvic transaminase remained within the 5% and 95% range of the normal values during the whole follow-up period of 35 days (data not shown).
Concentrations of melphalan in tissue and biofluids
The mean concentrations of melphalan in tumour and liver tissue at various time intervals after HAI and ILP respectively are presented in Figure 3a and 3b. ILP with 6 mg kg-l resulted in significantly higher concentrations in tumour tissue than HAI with the same dose (P<0.05) (Figure 3a) . (maximally about five times).
In plasma maximal concentrations of 14 gml-' were measured S min after HAI and concentrations of 1 jig mland 2 tg ml-' after washout and re-establishment of the normal liver circulation following ILP with 6 mg kg' and 12 mg kg-', respectively. Dose-response curve of melphalan The dose-response curve is shown in Figure 5 . The IDo value of CC531 for melphalan at 20min is 171igmlml and at 60 min 9 jg ml'l. Above 70 Lg ml-' both for 20 and 60 min incubation, no colonies were formed.
Effect ofmelphalan on tumour growth
Infusion or perfusion without drug had no effect on tumour growth: at day 42, the mean cross sectional area of the tumours was 350 ± 59 mm2, 379 ± 57 mm2 and 356 ± 91 mm2 in the untreated control, the hepatic artery infusion and the ILP group, respectively (Figure 6 ). HAI with 6 mg kg-of melphalan resulted in a significant retardation of tumour growth, but not in complete remissions. In contrast, 90% of the rats treated with 12mg kg-' in ILP setting had a complete remission from day 14 till sacrifice. In one rat, one tumour relapsed between day 14 and day 28, but this tumour grew very slowly in comparison with the control tumours ( Figure 6 ). Figure 4 Mean concentration of melphalan in perfusate (± s.e.) vs time curve in the two ILP treated groups: * 6 mg kg-' (n = 7) and x 12mgkg-' (n=6). i1ne adiference in nlepauc toxicLty DteWtee mVmI anu m--phalan treated rats, is in line with the serious hepatic toxicity (veno-occlusive disease) (Lazarus et al., 1982) or the mild, asymptomatic, and transient elevation of liver function tests (Lazarus et al., 1983; Leff et al., 1986) seen in patients treated with high dose mitomycin C or melphalan with autologous bone marrow transplantation. In these studies, mitomycin C was 3 to 4.5 times higher (60-90 mg m2) while melphalan was five times higher (180 mg m2) than the recommended single bolus doses i.v. without bone marrow support (Dorr & Fritz, 1980) . A second result from our study is that the distribution of melphalan was remarkably different from that observed in the earlier study with mitomycin C: (1) (ratio 0.6 to 0.9); (3) in contrast to the concentration of mitomycin C the concentration of melphalan was significantly lower in perfusate than in tumour and liver tissue. The uptake of melphalan by both liver and tumour tissue is apparently much faster than the uptake of mitomycin C. This difference may be explained by the active transport of melphalan into the cell mediated by two amino acid carrier systems (Begleiter et al., 1979; Goldenberg et al., 1979; Vistica, 1979) . This active transport could also explain the significant difference between the concentrations in tissue and perfusate. Furthermore, the difference in the concentration in tumour and liver tissue may be due to a difference between the active transport capacity of tumour and liver cells.
In this study, the mean (± s.e.) peak concentration of melphalan in perfusate was 42 ± 7 Lg ml -at t = 5 min in isolated liver perfusion with 12 mg kg'. This is three times higher than the highest plasma concentration reported in patients receiving 140 to 180 mg m2 i.v. (Taha et al., 1983; Gouyette et al., 1986) , and six to ten times higher than the maximum plasma concentrations measured in patients receiving conventional i.v. doses (0.5 to 0.6 mg kg-'; 10 to 20 mg mI2l) ( Minor et al., 1985) . Furthermore, the peak concen-I without drug (n = 4); O ILP without tration in the perfusate of the four patients treated with with 6 mg kg-' (n = 9); and x ILP with 0.5 mg kg-' body weight in isolated liver perfusion was 12 to nly in the ILP group complete remissions 60 jg ml' (Hafstrom et al., 1990) . Plasma and perfusate en). concentrations are well within the range of plasma and perfusate concentrations measured in patients. These concentrations are much higher than those achieved with i.v. administration of maximally tolerated doses in combination with autologous bone marrow transplantation. Different studies evaluating the antitumour effect of melwe found that in contrast to earlier phalan in vivo and in vitro using colony forming assays cin C (Marinelli et al., 1990a) , hepatic showed steep dose response curves (Greig et al., 1988 ; Bates e limiting after ILP with melphalan.
& Mackillop, 1990) . In most in vitro studies tumour cell dose limiting suggesting a significant survival was less than 0.1% after 20 min to 1 h exposure with elphalan.
relatively low concentrations of melphalan (less than (1980) demonstrated high concentra-20 jig ml-') (Barlogie & Drewinko, 1977; Zwelling et al., n bile of rats. Re-absorption of the 1979; Millar et al., 1986; Bates & Mackillop, 1990) ILP with mitomycin C also resulted in complete remissions in rats (Marinelli et al., 1991) . The technique of isolated liver perfusion has been already extensively and successfully tested in patients by different groups (Aigner et al., 1988; Hafstr6m et al., 1990 ) without serious (post-) operative complications. The best clinical results (however still preliminary, phase I/II) were obtained administering mitomycin C (Aigner et al., 1988) . In 1990 we started a phase I/IT trial with mitomycin C in ILP. No serious operative morbidity was encountered, mean hospitalisation was less than 2 weeks and objective responses were seen in six out of seven evaluable patients (manuscripts in preparation). Unfortunately, ILP with mitomycin C was associated with hepatotoxic side effects in man as in rats (Marinelli et al., 1990a) .
In conclusion, this study demonstrates that with ILP highly effective concentrations of melphalan can be achieved in tumour tissue in a dose range for which hepatic toxicity is negligible. These results suggest that melphalan is preferable to mitomycin C in the high dose chemotherapeutic treatment of liver metastases in ILP setting. Whether the results with melphalan are even more favourable if the same dose is administered as a 25 min continuous infusion instead of as a bolus in the hepatic artery will be investigated. This will be studied in HAI as well as in ILP setting. Furthermore, a clinical phase I/TI study of isolated liver perfusion will be started with melphalan.
